Catalio Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Catalio Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-577,808	Closed	-$19.3M	–	48
2026 Q1	$19.3M	Buy	577,808 +217,468	+60%	+$8.53M	4.04%	9
2025 Q4	$16.7M	Sell	360,340 -57,905	-14%	-$3.17M	2.95%	12
2025 Q3	$28.3M	Buy	418,245 +8,301	+2%	+$615K	5.23%	6
2025 Q2	$34.3M	Buy	409,944 +248,982	+155%	+$18.6M	7.2%	3
2025 Q1	$11.5M	Buy	+160,962	New	+$7.84M	2.8%	15

Catalio Capital Management's SLNO Position: Q2 2026 in Review

Catalio Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 577,808 shares — an estimated $19.3M sold.

Catalio Capital Management first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $34.3M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Catalio Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Catalio Capital Management sold 577,808 Soleno Therapeutics shares in Q2 2026, an estimated $19.3M.
Catalio Capital Management first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
Catalio Capital Management's Soleno Therapeutics position peaked at $34.3M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.